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Introduction
Drug treatments for overactive bladder (OAB) may
fail because of non-adherence or discontinuation.
These issues are frequently observed in clinical prac-
tice and were exempliﬁed in a recent evaluation of
both the extended-release (ER) and immediate-
release formulations of the most commonly used
antimuscarinic agents for OAB, oxybutynin and
tolterodine, in a regional managed healthcare plan.
One of the conclusions was that persistence overall
was low and more patient-reported data on outcomes
of OAB drug therapy are needed to improve under-
standing of non-adherence and discontinuations (1).
In particular, the patient’s perception of effectiveness
and tolerability may be a useful tool to predict
whether patients stay on treatment or not.
Amongst newer antimuscarinic agents, darifena-
cin has been identiﬁed as having particularly high
in vitro selectivity for the M3 muscarinic receptor
subtype thought to be responsible for detrusor
contraction (2,3). The efﬁcacy, tolerability and safety
of darifenacin in the treatment of OAB are well-
established.
For some OAB patients, switching to another
antimuscarinic could potentially achieve improvement
in their symptoms. However, data demonstrating that
patients already dissatisﬁed with one particular OAB
treatment may beneﬁt from the use of another agent
are often lacking. Here, we evaluated patient reports of
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SUMMARY
Introduction and objective: Patient perception of overactive bladder (OAB)
treatment outcomes can be a useful indicator of beneﬁt and may help drive persis-
tence on treatment, which is known to be poor in OAB. It remains unclear
whether OAB patients dissatisﬁed with one antimuscarinic can achieve satisfaction
with another and supporting data are limited. This study investigated patient-
reported outcomes and clinical parameters during darifenacin treatment in OAB
patients who expressed dissatisfaction with prior extended-release (ER) oxybutynin
or tolterodine therapy (administered for ‡ 1 week within the past year). Methods:
This open-label study was conducted in darifenacin-naı¨ve OAB patients. Patients
received 7.5 mg darifenacin once daily with the possibility of up-titrating to 15 mg
after 2 weeks, for up to 12 weeks. Efﬁcacy parameters included the Patient’s Per-
ception of Bladder Condition (PPBC), patient satisfaction with treatment, micturi-
tion frequency and number of urgency and urge urinary incontinence (UUI)
episodes. Adverse events (AEs) were also recorded. Results: In total, 497 patients
were treated (84.1% women). Darifenacin treatment resulted in statistically signiﬁ-
cant improvements in PPBC scores, micturition frequency, urgency and UUI epi-
sodes from baseline at 12 weeks. The improvements were similar for patients
previously treated with oxybutynin ER or tolterodine ER. More than 85% of
patients expressed satisfaction with darifenacin. As noted in other studies, the
most common AEs were dry mouth and constipation, but these infrequently
resulted in treatment discontinuation, which was low overall. Conclusions: In this
study, PPBC score and OAB symptoms were signiﬁcantly improved, and satisfaction
was high during treatment with darifenacin (7.5⁄15 mg) in patients who were dis-
satisﬁed with the previous antimuscarinic treatment.
What’s known
• It has been suggested that treatment with the
most commonly used antimuscarinic agents for
overactive bladder, extended- and immediate-
release (ER and IR) oxybutynin and tolterodine,
may be unsuccessful because of issues with
patient non-compliance and discontinuation
before maximal therapeutic beneﬁt can be
achieved.
• Data demonstrating that patients dissatisﬁed with
one particular OAB treatment may beneﬁt from
the use of another antimuscarinic are lacking.
What’s new
• This is the ﬁrst study to show that darifenacin
treatment can be associated with signiﬁcant
improvements from baseline in OAB symptoms,
patients’ perception of treatment outcome and
treatment satisfaction in patients who had
expressed dissatisfaction with prior ER
antimuscarinic therapy.
• This study utilises a unique patient satisfaction
scale, designed to resemble real-life questions
posed by a physician.
Linked Comment: Staskin. Int J Clin Pract 2008; 62: 1639–40.
doi: 10.1111/j.1742-1241.2008.01893.x
ORIGINAL PAPER
ª 2008 The Authors
1664 Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, November 2008, 62, 11, 1664–1674treatment beneﬁt and satisfaction with treatment,
clinical efﬁcacy, tolerability and safety parameters dur-
ing darifenacin treatment in an open-label, 12-week
study in patients who had expressed dissatisfaction
with efﬁcacy and⁄or side effects with prior treatment
with ER formulations of oxybutynin or tolterodine for
OAB. These data are supplemented by a novel measure
of patient satisfaction, a variable which, in clinical
practice, can be directly related to patient adherence
and persistence with therapy across diverse medical
specialities.
Materials and methods
Study design
This was a 12-week, open-label, single-arm, multi-
centre study to evaluate the patient’s perception of
treatment beneﬁts with darifenacin treatment in
patients with OAB who had expressed dissatisfaction
with prior treatment with ER formulations of oxybu-
tynin or tolterodine for reasons including insufﬁcient
efﬁcacy and adverse events (AEs) or both.
The study (NCT00366002) was conducted in 78
centres in the USA between June 2006 and September
2007, in accordance with the International Conference
on Harmonisation Harmonised Tripartite Guidelines
for Good Clinical Practice, with applicable local regu-
lations and with the ethical principles laid down in
the Declaration of Helsinki. Written informed consent
was obtained from each study participant.
Patients
The study population consisted of men and women
(‡ 18 years of age) with OAB symptoms [an average
of ‡ 8 micturitions⁄24 h and ‡ 1 urgency epi-
sode⁄24 h, with or without urgency urinary inconti-
nence (UUI) episodes] for at least 6 months prior to
randomisation, and with a baseline score of ‡ 2o n
the Patient Perception of Bladder Condition (PPBC)
questionnaire at screening. To be included in the
study, patients were required to be naı ¨ve to darifena-
cin treatment, to have received at least 1 week of
treatment with oxybutynin ER or tolterodine ER
within the year prior to this trial and to report that
they were dissatisﬁed with the most recent of these
treatments (assessed by response to a Patient’s Previ-
ous Treatment Assessment question at study visit 1).
Patient retention on treatment was expected to be
high because of their participation in an open-label
trial.
Patients with a mean daily urinary volume
> 3000 ml or a mean volume voided⁄micturition of
> 300 ml, as veriﬁed in the micturition diary for two
consecutive days prior to baseline, were excluded, as
were those with clinically predominant and bother-
some stress urinary incontinence, urinary retention,
clinically signiﬁcant bladder outlet obstruction, an
indwelling catheter or intermittent self-catheterisa-
tion. Those with other signiﬁcant medical problems
or urogenital conditions, including neurogenic blad-
der, cystocele or distal pelvic organ prolapse, fre-
quent urinary tract infections (‡ 3 over the
preceding year) or urogenital surgery in the previous
year or unexplained haematuria at screening, were
also excluded. Participation in a bladder-training
programme or any electro-stimulation therapy within
2 weeks prior to screening was also prohibited.
Women of childbearing age were required not to be
pregnant or nursing, and to be using acceptable
methods of contraception.
Concomitant treatments were also restricted; the
use of drugs known to affect mainly urinary bladder
function (e.g. anticholinergics, antispasmodics, sero-
tonin-noradrenaline-reuptake-inhibitors) was prohib-
ited at any time during the study, but stable doses of
alpha blockers or 5-alpha-reductase inhibitors were
permitted for patients with benign prostatic hyper-
plasia. Treatments prohibited during the prescreening
period included cholinergic agonists, cholinesterase
inhibitors (e.g. bethanecol, donepezil and rivastig-
mine), potent inhibitors of cytochrome CYP3A4 (e.g.
ketoconazole, itraconazole, ritonavir, nelﬁnavir, clari-
thromycin and nefazadone), potent P-glycoprotein
inhibitors (e.g. cyclosporine and verapamil), drugs
with signiﬁcant anticholinergic side effects (e.g. tricy-
clic antidepressants, selective-serotonin-reuptake-
inhibitors and ﬁrst generation antihistamines) or any
other investigational drug.
Treatment and assessments
After a prescreening⁄washout period during which
prohibited medications were discontinued (at study
visit 2), patients were asked to complete a bladder
diary for 5 consecutive days to establish baseline
symptoms and OAB severity during the 7 days prior
to the baseline visit (visit 3). Eligible patients then
received darifenacin 7.5 mg once daily (qd) for the
ﬁrst 2 weeks postbaseline; subsequently (at visit 4)
voluntary up-titration to darifenacin 15 mg qd was
permitted if the patient required additional efﬁcacy,
and treatment was well tolerated. Down-titration of
darifenacin was not permitted. The remaining
patients received darifenacin 7.5 mg qd throughout
the study (Figure 1).
The primary efﬁcacy variable was the change from
baseline to study end (visit 6) in the score on the
PPBC, a validated six-point categorical Likert scale
questionnaire (4) in which patients select one of six
categories that best describe their bladder condition,
ranging from ‘does not cause me any problems at
Re-use of this article is
permitted in accordance
with the Creative Commons
Deed, Attribution 2.5,
which does not permit
commercial exploitation.
Darifenacin for dissatisﬁed patients 1665
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, November 2008, 62, 11, 1664–1674all’ to ‘causes me many severe problems’. Patients
completed the PPBC questionnaire at baseline (visit
3) and after 6 and 12 weeks of treatment (at visits 5
and 6 respectively).
Patients also completed an exploratory question-
naire developed for this study, the Patient Satisfaction
with Treatment Beneﬁt (PSTB) questionnaire, after
12 weeks of treatment (visit 6). Prior to being imple-
mented in the study, the PSTB underwent pilot testing
in which it was shown to contain items that are clearly
understood and relevant to OAB sufferers. Part I of
the PSTB assesses overall satisfaction with the treat-
ment beneﬁts received from therapy using a ﬁve-point
Likert scale, with ﬁve response options ranging from
‘extremely satisﬁed’ to ‘not at all satisﬁed’. Part II of
the PSTB contains 23 items that assess patient satisfac-
tion with treatment for improving the effects of OAB
on their sleep, daily activities, emotions and reducing
the level of coping behaviours (e.g. pad usage), using
the same ﬁve-point Likert scale, with an additional
response option of ‘not applicable’.
Efﬁcacy was also evaluated relative to baseline after
2, 6 and 12 weeks of treatment (at visits 4, 5 and 6
respectively) using data on micturition frequency,
urgency and UUI episodes collected in a 5-day blad-
der symptom paper diary over ﬁve consecutive days
during the 7 days prior to the study visit. UUI epi-
sodes were recorded by checking both urinary leak
and urgency. Tolerability and safety were monitored
throughout the trial based on AEs, treatment
discontinuations, vital signs and laboratory para-
meters recorded at each study visit.
Statistical analysis
The intent-to-treat population comprised all patients
who received at least one dose of study drug. A study
sample size of 398 was calculated to have 90% power
to detect a signiﬁcant change from baseline in PPBC
score, using Wilcoxon’s signed-rank test and a two-
sided 5% signiﬁcance level. Allowing for a 20%
withdrawal rate, 500 patients were calculated to be
required for the study.
The change from baseline to study end (visit 6) in
PPBC (primary efﬁcacy variable) was analysed by
Wilcoxon’s signed-rank test for all patients in the
intent-to-treat population who responded to the
PPBC questionnaire both at baseline (visit 3) and
postbaseline (visits 5 and⁄or 6). If visit 6 data were
missing, visit 5 data were carried forward (if avail-
able). Odds for improvement in PPBC score were
calculated as the ratio between the proportion of
patients with an improvement and those without
improvement, and used to calculate the ratio
between odds for improvement in the two previous
treatment groups (oxybutynin ER vs. tolterodine
ER). Logistic regression analysis of the resulting odds
ratio was used to detect differences between groups.
These analyses were also conducted post hoc for the
subset of patients who were receiving oxybutynin ER
or tolterodine ER at screening.
Figure 1 Study design overview. qd, once daily; PPBC, Patient Perception of Bladder Condition; PSTB, Patient Satisfaction
with Treatment Beneﬁts
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included the change in PPBC from baseline to visit
5, and the percentage of patients categorised as hav-
ing ‘improvement’, ‘no change’ and ‘deterioration’ at
both visits 5 and 6, together with the corresponding
95% conﬁdence intervals (CI). The percentage of
patients categorised as ‘satisﬁed’ based on their
responses to the PSTB (part I) was also calculated
and explored by a logistic regression model adjusting
for age, gender and stratum (previous treatment with
oxybutynin ER or tolterodine ER).
Clinical symptom outcomes based on bladder
diary responses (number of micturitions⁄day,
urgency episodes⁄week and UUI episodes⁄week)
were analysed by Wilcoxon’s signed-rank test at vis-
its 5 and 6 and by Poisson regression adjusting for
baseline, age, gender and previous treatment.
Patients without UUI episodes at baseline were not
included in the analysis of UUI episodes. In addi-
tion, a post hoc analysis was conducted to evaluate
the magnitude of change from baseline to study
end in bladder diary parameters (micturition fre-
quency, urgency and UUI episodes) in patients
reporting a change in PPBC score of 0, 1, 2 or 3.
AEs were summarised descriptively for the safety
population, comprising all patients who received at
least one dose of darifenacin. The results are pre-
sented here for all prespeciﬁed variables included in
the statistical analysis plan and the post hoc analyses
mentioned.
Results
Patients
Of 500 patients enrolled, 497 patients received study
drug and comprised the intent-to-treat and safety
populations of the study. This included 218 patients
previously treated with oxybutynin ER and 279 pre-
viously treated with tolterodine ER, of whom
approximately 34% (75⁄218 and 95⁄279 respectively)
were still receiving this treatment at the screening
visit. These two subsets were comparable in baseline
demographics with the overall study population
(Table 1). There was no evidence of UUI episodes in
17.1% of all patients at baseline.
A total of 60 patients discontinued the study pre-
maturely (31 previously treated with oxybutynin ER
and 29 previously treated with tolterodine ER). The
main reasons for discontinuation were AEs (4.4%),
withdrawal of consent (2.6%), protocol deviation
(1.8%) and unsatisfactory therapeutic effect (1.8%),
and were comparable between patients previously
treated with oxybutynin ER or tolterodine ER except
for the number of protocol deviations (eight patients
previously treated with oxybutynin ER vs. one
previously treated with tolterodine ER). Patient
disposition is summarised in Figure 2.
The darifenacin dose was increased to 15 mg qd
for 62.6% of the patients remaining in the study at
2 weeks (302⁄482), comprising 65.9% (137⁄208) pre-
viously treated with oxybutynin ER and 60.2%
(165⁄274) previously treated with tolterodine ER.
Efﬁcacy: patient-reported outcomes
The PPBC scores for the change in bladder condition
from baseline (Table 2) were signiﬁcantly reduced by
12 weeks of darifenacin treatment (p < 0.0001).
Almost identical, statistically signiﬁcant ﬁndings were
observed in a post hoc analysis of patients still receiv-
ing their previous antimuscarinic therapy at screen-
ing (p < 0.0001). This level of improvement was also
achieved after 6 weeks of treatment (visit 5), with a
median score of 3.0, and a mean ± standard devia-
tion (SD) score of 3.1 ± 1.20 (p < 0.0001 vs. base-
line). At both 6 and 12 weeks, the median change in
PPBC from baseline was )1.0 and the mean change
was )1.4. This corresponds to a change on the PPBC
scale from ‘my bladder causes me some moder-
ate⁄severe problems’ (baseline mean score = 4.5) to
‘my bladder causes me some minor problems’ (visit
6 mean score = 3.1).
The effect of darifenacin in improving PPBC was
evident regardless of previous treatment (Table 2). In
a logistic regression analysis, the odds (and 95% CI)
for improvement in PPBC amongst previous recipi-
ents of oxybutynin ER or tolterodine ER were 2.08
(1.48, 2.92) and 1.77 (1.29, 2.43) respectively. There
was no statistically signiﬁcant difference between
the two prior treatment groups on PPBC, with an
odds ratio for improvement in oxybutynin : toltero-
dine recipients of 1.17 (95% CI: 0.78, 1.77).
In line with these ﬁndings, evaluation of individual
responses indicated that most patients (356⁄497,
72.8%) reported an improvement in PPBC, with 113
(23.1%) reporting no change after 12 weeks of treat-
ment, and 20 patients (4.1%) reporting an increase
in their PPBC score (i.e. symptom deterioration). In
addition, 110 of the 230 patients (47.8%) reporting
‘severe’ or ‘many severe’ problems on the PPBC
questionnaire at baseline shifted to ‘does not cause
me any problems at all’, ‘causes me minor problems’
or ‘causes me some minor problems’ after 12 weeks
of treatment with darifenacin.
Assessment of overall satisfaction with treatment
beneﬁt using the PSTB showed that 405 patients
(85.6%) were ‘satisﬁed’ with darifenacin treatment
after 12 weeks, and 68 (14.4%) were ‘not satisﬁed’.
Satisfaction levels were not statistically signiﬁcantly
inﬂuenced by previous treatment: odds for reporting
satisfaction (and 95% CI) were 4.35 (2.90, 6.53)
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(3.50, 7.80) for tolterodine ER recipients, represent-
ing an odds ratio (95% CI) of 0.83 (0.50, 1.40). Sim-
ilarly, satisfaction with individual aspects of OAB
condition in part II of the PSTB questionnaire after
12 weeks was evident, with only minor differences
according to previous treatment received (data not
shown).
Efﬁcacy: bladder diary parameters
Darifenacin treatment for 12 weeks resulted in signif-
icant improvements in micturition frequency,
urgency episodes and UUI episodes compared with
baseline, both for the overall study population and
after stratiﬁcation by prior treatment (all p < 0.0001)
(Table 2). Improvements in these OAB symptoms
reached statistical signiﬁcance within 2 weeks of ini-
tiating darifenacin treatment and appeared to
improve further after 6 and 12 weeks (Figure 3). An
informal post hoc analysis indicated that the reduc-
tions in each of the three micturition variables in the
overall study population at study end were consis-
tently associated with increasing degree of improve-
ment in PPBC scores.
In a Poisson regression analysis, after adjustment
for baseline, gender, age and previous therapy, the
efﬁcacy of darifenacin on micturition frequency did
not differ signiﬁcantly between patients according to
previous oxybutynin ER or tolterodine ER treatment.
However, compared with patients previously given
oxybutynin ER, patients previously given tolterodine
ER experienced signiﬁcantly fewer urgency episodes
at study end (oxybutynin vs. tolterodine: adjusted
mean 3.4 vs. 3.0, median 2.2 vs. 1.8, p = 0.0296) and
signiﬁcantly fewer UUI episodes after 2 weeks
(adjusted mean 8.1 vs. 7.9, median 4.2 vs. 3.5,
p = 0.0426), 6 weeks (adjusted mean 6.1 vs. 4.9,
median 2.8 vs. 1.4, p < 0.0001) and 12 weeks of
Table 1 Baseline demographics and characteristics for the study populations according to the previous OAB treatment
Parameter
Previous treatment
All patients Oxybutynin ER Tolterodine ER
Total study population n = 218 n = 279 n = 497
Age
Mean ± SD, years 61.3 ± 12.8 60.6 ± 12.7 60.9 ± 12.7
Range, years 25–89 24–84 24–89
‡ 65 years, n (%) 97 (44.5) 114 (40.9) 211 (42.5)
Women, n (%) 178 (81.7) 240 (86.0) 418 (84.1)
Race, n (%)
Caucasian 202 (92.7) 255 (91.4) 457 (92.0)
Black 10 (4.6) 20 (7.2) 30 (6.0)
Other 6 (2.8) 4 (1.4) 10 (2.0)
Reason for dissatisfaction with the previous treatment
Intolerable side effects 20 (9.2) 27 (9.7) 47 (9.5)
Insufﬁcient efﬁcacy 166 (76.1) 217 (77.8) 383 (77.1)
Both insufﬁcient efﬁcacy and intolerable side effects 32 (14.7) 35 (12.5) 67 (13.5)
OAB parameters, median
Micturitions⁄day 10.2 10.4 10.2
Urgency episodes⁄day 5.6 5.4 5.6
UUI episodes⁄week 16.8 16.8 16.8
Patients receiving prior ER antimuscarinic therapy at screening n =7 5 n =9 5 n = 170
Age
Mean ± SD, years 63.3 ± 12.5 61.5 ± 12.6 62.3 ± 12.5
Range, years 32–85 31–84 31–85
‡ 65 years, n (%) 40 (53.3) 41 (43.2) 81 (47.6)
Women, n (%) 60 (80.0) 82 (86.3) 142 (83.5)
Race, n (%)
Caucasian 72 (96.0) 86 (90.5) 158 (92.9)
Black 2 (2.7) 7 (7.4) 9 (5.3)
Other 1 (1.3) 2 (2.1) 3 (1.8)
ER, extended-release; OAB, overactive bladder; PPBC, patient perception of bladder condition; SD, standard deviation; UUI, urgency
urinary incontinence.
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median 2.8 vs. 1.4, p < 0.0001) respectively.
Further investigation indicated that this apparently
greater efﬁcacy of darifenacin on UUI episodes in
patients previously treated with tolterodine ER also
occurred in patients with more severe OAB at base-
line (i.e. those reporting at least seven UUI episodes
per week at baseline). Amongst such patients previ-
ously given oxybutynin ER (n = 129) vs. tolterodine
ER (n = 159), the number of UUI episodes was rela-
tively high after 2 weeks on darifenacin 7.5 mg
(adjusted mean 10.3 vs. 10.7, median 5.6 vs. 7.0);
UUI episodes subsequently decreased to 7.9 vs. 6.6
(4.2 vs. 2.8) after 6 weeks and 8.6 vs. 6.8 (2.8 vs. 2.8)
after 12 weeks, respectively. However, there were no
signiﬁcant differences according to prior treatment
in darifenacin response rates at any cut-off rate, i.e.
the proportion of patients achieving at least 50%,
70% or 90% reduction in UUI episodes per week
(Figure 4).
The response to darifenacin treatment in terms of
dry days was similar between prior oxybutynin ER
and tolterodine ER recipients, with 64.2% vs. 64.5%
of patients achieving at least three consecutive dry
days respectively. The data suggested that more tolte-
rodine ER- than oxybutynin ER-pretreated patients
achieved a state approaching continence and bladder
control after 12 weeks of treatment with darifenacin,
although the clinical relevance of this ﬁnding
remains to be determined. At study end, 44.2% vs.
51.0% previous oxybutynin ER vs. previous toltero-
dine ER recipients achieved at least ﬁve consecutive
dry days on darifenacin and 40.6% vs. 48.2%
achieved < 8 voids per day.
Figure 2 Subject disposition and ﬂow. ER, extended-release; ITT, intent-to-treat. *Three patients were included but did
not receive treatment
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The most common AEs during darifenacin treatment
were dry mouth (reported by 20.1% of patients) and
constipation (14.1%; Table 3). Both events were
reported slightly less frequently by patients previously
treated with oxybutynin ER (16.1% dry mouth and
11.0% constipation) than tolterodine ER (23.3% and
16.5% respectively). These AEs were well tolerated,
infrequently leading to treatment discontinuation;
only 10 (4.6%) and 12 (4.3%) patients previously
treated with oxybutynin ER or tolterodine ER dis-
continued darifenacin treatment because of an AE,
respectively, and overall only 1.6% of patients dis-
continued because of dry mouth and 0.8% because
of constipation. There were no deaths during the
study and no clinically relevant changes in laboratory
parameters or vital signs. Seven patients experienced
Table 2 Inﬂuence of up to 12 weeks of ﬂexible-dose
darifenacin treatment on PPBC and clinical symptoms
Previous treatment
All patients
(n = 497)
Oxybutynin
ER
(n = 218)
Tolterodine
ER
(n = 279)
PPBC
Total study population
Patients, n 214 275 489
Baseline
Mean ± SD 4.6 ± 0.79 4.5 ± 0.76 4.5 ± 0.77
Median 5.0 4.0 4.0
12 weeks
Mean ± SD 3.1 ± 1.24 3.1 ± 1.27 3.1 ± 1.25
Median 3.0 3.0 3.0
Change
Mean ± SD )1.4 ± 1.26 )1.4 ± 1.33 )1.4 ± 1.30
Median )1.0 )1.0 )1.0
p-value* < 0.0001 < 0.0001 < 0.0001
Patients receiving prior ER antimuscarinic therapy at screening
Patients, n 75 94 169
Baseline
Mean ± SD 4.6 ± 0.85 4.6 ± 0.82 4.6 ± 0.84
Median 5.0 5.0 5.0
12 weeks
Mean ± SD 3.2 ± 1.26 2.9 ± 1.31 3.0 ± 1.29
Median 3.0 3.0 3.0
Change
Mean ± SD )1.4 ± 1.41 )1.6 ± 1.34 )1.5 ± 1.37
Median )1.0 )2.0 )1.0
p-value* < 0.0001 < 0.0001 < 0.0001
Micturitions⁄day
Patients, n 208 274 482
Baseline
Mean ± SD 10.9 ± 2.90 10.8 ± 2.60 10.8 ± 2.73
Median 10.2 10.4 10.2
12 weeks
Mean ± SD 8.9 ± 2.60 8.4 ± 2.56 8.6 ± 2.59
Median 8.4 8.2 8.2
Change
Mean ± SD
(absolute)
)2.0 ± 2.23 )2.2 ± 2.50 )2.2 ± 2.39
Median
(absolute)
)1.8 )2.0 )2.0
Median (%) )17.4 )21.2 )19.5
p-value* < 0.0001 < 0.0001 < 0.0001
Urgency episodes⁄day
Patients, n 208 274 482
Baseline
Mean ± SD 6.3 ± 3.41 6.2 ± 3.30 6.2 ± 3.34
Median 5.6 5.6 5.6
12 weeks
Mean ± SD 3.4 ± 3.45 3.0 ± 3.34 3.2 ± 3.39
Median 2.2 1.8 1.8
Table 2 (continued)
Previous treatment
All patients
(n = 497)
Oxybutynin
ER
(n = 218)
Tolterodine
ER
(n = 279)
Change
Mean ± SD
(absolute)
)2.8 ± 2.97 )3.2 ± 3.35 )3.1 ± 3.20
Median
(absolute)
)2.6 )3.0 )2.8
Median (%) )55.5 )64.0 )61.6
p-value* < 0.0001 < 0.0001 < 0.0001
UUI episodes⁄week
Patients, n 175 227 402
Baseline
Mean ± SD 16.7 ± 14.81 16.5 ± 16.15 16.6 ± 15.56
Median 11.2 11.2 11.2
12 weeks
Mean ± SD 6.8 ± 11.49 5.0 ± 9.73 5.8 ± 10.56
Median 2.8 1.4 1.4
Change
Mean ± SD
(absolute)
)9.9 ± 13.89 )11.5 ± 13.25 )10.8 ± 13.54
Median
(absolute)
)8.4 )8.4 )8.4
Median (%) )83.3 )88.0 )85.7
p-value* < 0.0001 < 0.0001 < 0.0001
*p-value for absolute (PPBC) or % change from baseline using
the Wilcoxon signed-rank test. Data at 12 weeks were calcu-
lated using last-observation carried forward method. ER, exten-
ded-release; PPBC, Patient Perception of Bladder Condition; SD,
standard deviation; UUI, urgency urinary incontinence.
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related by the investigator.
Discussion
In this study involving patients who expressed dissatis-
faction with prior OAB treatment with oxybutynin ER
or tolterodine ER because of insufﬁcient efﬁcacy or
tolerability problems or both, open-label darifenacin
administration for 12 weeks resulted in improvements
in patient perceptions of their bladder condition that
correlated with improvements in clinical symptoms
(micturition frequency, urgency and UUI episodes).
These improvements were accompanied by a favour-
able tolerability proﬁle, resulting in a large majority of
patients (approximately 86%) reporting satisfaction
with darifenacin treatment.
The improvements observed in this study were
comparable to those previously reported in other stud-
ies with antimuscarinic agents. For example, the mean
PPBC score decreased from baseline 4.6 to 3.1 after
12 weeks of darifenacin treatment in the present study,
and from 4.4 to 2.9 after 12 weeks of solifenacin treat-
ment in the VOLT study (5). In addition, the reduc-
tions in micturition frequency, urgency and UUI
episodes were comparable to those seen in the previ-
ous darifenacin studies using the same dosing regimen
(6,7). OAB symptom improvements in our study were
also comparable to the ﬁndings reported in the VESl-
care Efﬁcacy and Research Study US (VERSUS) study,
in which patients dissatisﬁed with tolterodine treat-
ment were switched to solifenacin (8), and a long-term
extension study in which patients were permitted to
switch to open-label solifenacin following double-
blind tolterodine treatment (9).
The incidence and nature of AEs reported in this
study were consistent with those reported in earlier
clinical trials with darifenacin. These results are fur-
ther supported by high levels of persistence with
darifenacin therapy and well-maintained treatment
beneﬁt in previous long-term studies (over 2 years in
duration) (10,11).
This open-label study also evaluated levels of
patient satisfaction via the use of a novel exploratory
satisfaction scale (PSTB questionnaire), which was
designed to resemble real-life questions posed by a
physician. Patients were required to recall their experi-
ences of previous antimuscarinic treatment at base-
line, while PSTB responses were recorded at the end
of darifenacin treatment to determine whether these
patients expressing dissatisfaction with their previous
antimuscarinic achieved satisfaction with darifenacin.
PSTB results indicated that more than 85% of patients
expressed satisfaction with darifenacin treatment.
Patient satisfaction can be regarded as an impor-
tant indicator of the quality of care across diverse
medical specialities. Satisfaction with treatment is
inﬂuenced by a combination of many factors, which
go beyond traditional measures assessed in clinical
trials (i.e. improvement in symptoms, and the type,
frequency and severity of side effects). Interest in
patient perceptions of the efﬁcacy of their treatment
has grown in recent years, resulting in the recent
development by the Food and Drug Administration
(FDA) of guidance for the pharmaceutical industry
on the assessment of patient-reported outcomes in
clinical trials (12). Despite this, a consensus on the
best approach to assessing treatment satisfaction in
clinical practice is yet to be reached. This study pre-
sents a novel method to assess patient satisfaction
directly, which takes into account the real-life clinical
situations. In the majority of patients (65.8%),
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Figure 3 Efﬁcacy of darifenacin treatment on OAB
symptoms in the intent-to-treat population (LOCF
analysis), seen as: (A) daily micturition frequency, (B) daily
urgency episodes and (C) weekly UUI episodes. ER,
extended-release; UUI, urgency urinary incontinence
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study entry, but in the remaining cases, previous
treatment could have been discontinued up to a year
before study entry. In clinical practice, visits to the
physician commonly occur at intervals of 6–8 weeks
or longer, and consequently, the physician may
not see the patient within 1 week after a patient’s
decision to terminate treatment (the period recom-
mended for FDA analysis). Under these circum-
stances, the physician must rely on the patient’s
recall of his or her treatment satisfaction, in a similar
manner to the conduct of the present study. Simi-
larly, the PSTB questionnaire provided a snapshot of
patient perceptions of darifenacin treatment at
study end, resembling the situation encountered in
routine physician visits. However, administering the
questionnaire during a single visit does not permit
assessment of change in treatment perception over
time (or between one treatment and the next),
and this novel scale would beneﬁt from further
validation.
There are some weaknesses in this study that should
be noted. Patient satisfaction seen in this study may
reﬂect a response to a change in treatment, rather
than the speciﬁc drug per se, coupled with satisfaction
arising from a perceived improvement in overall care
and increased monitoring associated with participa-
tion in a clinical study. The drug costs of the previous
treatments may also have contributed to the lower
satisfaction with the previous therapy, compared with
free treatment provided during clinical trial participa-
tion. A longitudinal study design with consecutive
treatments and accurate recording of patient percep-
tions of outcomes immediately after terminating each
Figure 4 Different response levels for patients with ‡ 7 UUI episodes per week at baseline after 12 weeks of darifenacin
treatment, according to previous treatment received. ER, extended-release; UUI, urgency urinary incontinence
Table 3 Most frequent adverse events (‡ 2% of total population)
Preferred term
Previous oxybutynin
ER, N = 218, n (%)
Previous tolterodine
ER, N = 279, n (%)
Total, N = 497,
n (%)
Any AE(s) 119 (54.6) 171 (61.3) 290 (58.4)
Dry mouth 35 (16.1) 65 (23.3) 100 (20.1)
Constipation 24 (11.0) 46 (16.5) 70 (14.1)
Urinary tract infection 12 (5.5) 21 (7.5) 33 (6.6)
Headache 10 (4.6) 8 (2.9) 18 (3.6)
Nausea 5 (2.3) 11 (3.9) 16 (3.2)
Dyspepsia 5 (2.3) 8 (2.9) 13 (2.6)
Dry eye 2 (0.9) 9 (3.2) 11 (2.2)
Upper respiratory tract infection 5 (2.3) 5 (1.8) 10 (2.0)
AEs, adverse events.
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question whether more patients are satisﬁed following
darifenacin treatment than with their previous treat-
ment. As the discontinuation of prior ER antimuscari-
nic treatment could have taken place up to 1 year
before entry into the present study, patient recall of
satisfaction with the prior therapy may be unreliable.
However, despite the low numbers of patients still
receiving their previous antimuscarinic therapy at
study entry (before washout), primary outcomes in
this subset and the total study population were almost
identical. It would also be of interest to determine
whether patients switching to darifenacin remain
satisﬁed with continued treatment. Similarly, further
studies are warranted to determine whether the
proportion of satisﬁed patients and the duration of
satisfaction differ between antimuscarinic treatments.
The PSTB was developed with patient input and
piloted with patients to ensure that patients under-
stood the questionnaire items and that the items
measured parameters that were relevant to patients.
However, it has not been thoroughly validated as per
the FDA draft guidance for developing new patient-
reported outcomes in clinical trials (12). Further
research is needed to establish the validity and reli-
ability of the PSTB.
Patient-reported outcome measures are increas-
ingly being viewed as important measures of treat-
ment success, and indeed some have been described
as better than objective measures (such as urody-
namic testing) for gauging treatment efﬁcacy (13,14).
The present study utilised both a well-known, vali-
dated instrument (the PPBC) and a novel explor-
atory questionnaire (the PSTB), with both tools
indicating signiﬁcant levels of beneﬁt from darifena-
cin treatment relative to baseline, regardless of the
previous treatment received. These tools are particu-
larly important for observing outcomes from the
patient’s perspective, as they reﬂect subjective views
of treatment impact on all aspects of daily living and
individuals vary substantially in their desired out-
comes and priorities or goals of treatment.
In conclusion, the ﬁndings of this study indicate
that darifenacin 7.5⁄15 mg qd treatment can be asso-
ciated with signiﬁcant improvements from baseline
in OAB symptoms and patient’s perception of treat-
ment outcome in patients who have expressed dissat-
isfaction with prior ER antimuscarinic therapy. Thus,
darifenacin provides a valuable treatment option for
such patients.
Acknowledgements
The authors would like to thank the staff of the cen-
tres involved in this work and the clinical trial team
for their expert collaboration and the patients who
participated in the study. The authors would also like
to thank Jessica Colon of Novartis Pharmaceuticals
Corporation, Prem Chandra of Novartis Healthcare
(Mumbai) and Mary Goodsell of ACUMED
  for
their contribution to this manuscript. Funding for
this study and for the editorial and project manage-
ment services of ACUMED
  in the preparation of
this manuscript were provided by Novartis Pharma
AG.
Author contributions
N. Zinner and K. Kobashi were investigators in the
study, performed data review and interpretation of
the complete set of study data tables and results of
statistical analyses and provided input into and criti-
cal review of all manuscript drafts. All authors
approved the article for submission. U. Ebinger,
A. Viegas and M. Egermark were involved in the
study design, were responsible for the trial conduct,
oversaw the accuracy of the outputs and assisted
with drafting and critical review of the manuscript.
E. Quebe-Fehling was the Trial Statistician and was
involved in the study design and analysis of the data,
along with critical review of the manuscript. P. Koo-
chaki was involved in the development and imple-
mentation of the PSTB questionnaire and provided a
critical review of the manuscript.
References
1 D’Souza A, Smith MJ, Miller L-A, Doyle J, Ariely R. Persistence,
adherence, and switch rates among extended-release and immedi-
ate-release over-active bladder (OAB) medications in a regional
managed care plan. J Manag Care Pharm 2008; 14: 291–301.
2 Napier C, Gupta P. Darifenacin is selective for the human recom-
binant M3 receptor subtype (abstract). http://www.icsofﬁce.org/
publications/2002/pdf/445.pdf (accessed 27 August 2008).
3 Nelson CP, Gupta P, Napier CM, Nahorski SR. Functional selectiv-
ity of muscarinic receptor antagonists for inhibition of M3-medi-
ated phosphoinositide responses in guinea pig urinary bladder and
submandibular salivary gland. J Pharmacol Exp Ther 2004; 310:
1255–65.
4 Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the
patient perception of bladder condition (PPBC): a single-item glo-
bal measure for patients with overactive bladder. Eur Urol 2006;
49: 1079–86.
5 Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom
bother and health-related quality of life outcomes following soli-
fenacin treatment for overactive bladder: the VESIcare Open-Label
Trial (VOLT). Clin Ther 2006; 28: 1935–46.
6 Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A. Darifenacin
treatment of patients ‡65 years with overactive bladder: results of
a randomized, controlled, 12-week trial. Curr Med Res Opin 2007;
23: 2347–58.
7 Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose
titration with darifenacin, an M3-selective receptor antagonist. BJU
Int 2005; 95: 580–6.
8 Karram M, Chancellor M, Andoh M. Solifenacin reduces overactive
bladder symptoms and improves health-related quality of life in
Darifenacin for dissatisﬁed patients 1673
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, November 2008, 62, 11, 1664–1674patients previously treated with tolterodine (abstract). http://www.
icsofﬁce.org/publications/2006/pdf/0332.pdf (accessed 12 January
2007).
9 van Kerrebroeck P, Haab F, Millard R. Antimuscarinic therapy for
overactive bladder syndrome: possible beneﬁts of switching to soli-
fenacin (abstract). http://www.icsofﬁce.org/publications/2005/pdf/
0571.pdf (accessed 21 May 2008).
10 Haab F, Corcos J, Siami P et al. Long-term treatment with darifen-
acin for overactive bladder: results of a 2-year, open-label exten-
sion study. BJU Int 2006; 98: 1025–32.
11 Hill S, Elhilali M, Millard R, Lheritier K, Kawakami F, Steel M.
Long-term darifenacin treatment for overactive bladder in patients
aged 65 years and older: analysis of results from a 2-year, open-
label extension study. Curr Med Res Opin 2007; 23: 2697–704.
12 FDA Report. Guidance for Industry. Patient-Reported Outcome
Measures: Use in Medical Product Development to Support Labeling
Claims. http://www.fda.gov/CDER/GUIDANCE/5460dft.pdf (acces-
sed 27 August 2008).
13 Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported out-
comes in overactive bladder: importance for determining clinical
effectiveness of treatment. Urology 2006; 68: 3–8.
14 Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported
outcomes in overactive bladder: the inﬂuence of perception of
condition and expectation for treatment beneﬁt. Urology 2006; 68:
29–37.
Paper received April 2008, accepted July 2008
1674 Darifenacin for dissatisﬁed patients
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, November 2008, 62, 11, 1664–1674